{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-018735","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.441723+00:00","generated_at":"2026-06-05T19:52:52.321769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AVITA Medical Q4 commercial revenue up 50% to $14.1M; guides FY2024 rev $78.5-84.5M","bullets":["Commercial revenue Q4 $14.1M (+50% YoY); gross margin 87.3%.","Full-year 2023 commercial revenue $49.8M (+46% YoY); net loss $35.4M ($1.40/share).","Q1 2024 revenue guidance $14.8-15.6M; FY2024 guidance $78.5-84.5M (57-69% growth).","Expects RECELL GO FDA launch May 31, 2024; sales team to expand to 108.","Targeting cashflow breakeven and GAAP profitability no later than Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-018735","json":"https://secwatch.observer/filing/0000950170-24-018735.json","markdown":"https://secwatch.observer/filing/0000950170-24-018735.md","text":"https://secwatch.observer/filing/0000950170-24-018735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/rcel-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:52:52.321769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"117e44aeac16b040b4bd61fca1676a894bf8c19b","claim":"AVITA Medical, Inc. reported Fourth Quarter 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS Net loss was $7.1 million, or a loss of $0.28 per basic and diluted share.","evidence_excerpt":"reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2023"},{"label":"Revenue","value":"Commercial revenue increased approximately 50% to $14.1 million"},{"label":"EPS","value":"Net loss was $7.1 million, or a loss of $0.28 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4167c89866017119350cc01a540994b5e83de36e","claim":"AVITA Medical, Inc. reported first quarter 2024 results: revenue Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million. Guidance initiated.","evidence_excerpt":"Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth of approximately 42% to approximately 50% over the same period in the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"750b6d8b2afb445908ef1e4e39d75361e75fc421","claim":"AVITA Medical, Inc. reported full-year 2024 results: revenue Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million. Guidance initiated.","evidence_excerpt":"Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million, reflecting growth of approximately 57% to approximately 69% over the full-year 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Revenue","value":"Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7db5cf8fb2a63443756f39f16bb8a374459c2ce0","claim":"AVITA Medical, Inc. reported Full-Year 2023 results: revenue Commercial revenue increased by 46% to $49.8 million, EPS Net loss for the full-year 2023 was $35.4 million, or a loss of $1.40 per basic and diluted share.","evidence_excerpt":"50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8 million compared to the same period in 2022 • Gross profit margin of 84.5% • As of December 31, 2023, approximately $89.1 million in cash, cash equivalents, and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2023"},{"label":"Revenue","value":"Commercial revenue increased by 46% to $49.8 million"},{"label":"EPS","value":"Net loss for the full-year 2023 was $35.4 million, or a loss of $1.40 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"da66ec230be1feefe1641cd100f86038eafe3da8","claim":"AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS loss of $0.28 per basic and diluted share.","evidence_excerpt":"reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year ended December 31, 2023"},{"label":"Revenue","value":"Commercial revenue increased approximately 50% to $14.1 million"},{"label":"EPS","value":"loss of $0.28 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}